Community project funding/congressionally directed spending - construction - the focus of this grant application is enhancing the resiliency of mriglobal's biorepository capability at an owned…

Community project funding/congressionally directed spending - construction - the focus of this grant application is enhancing the resiliency of mriglobal's biorepository capability at an owned facility located at 1222 ozark street, north kansas city (NKC), MO. Mriglobal's NKC facility is a modern 87,000 SQ. FT. Facility that includes a sophisticated biorepository, cgmp pharmaceutical warehouse space, administrative offices, and other capabilities supporting mriglobal's mission to use science and technology to create solutions for a safer, healthier, more sustainable world. This biorepository resiliency investment will advance management of biologics, biological samples (biospecimens), and the regional supply chain supporting clinical studies aimed at advancing the newest technologies in medical treatments and disease prevention. Mriglobal's growth over the next decade will positively impact the regional kansas city economy by increasing the number of high paying jobs and services, maintaining our leadership as a strong and active corporate citizen, and continuing to support the kansas city region's science, technology, engineering and math (stem) education programs and workforce development. Mriglobal is a 501C3 not-for-profit organization that conducts more than $110M/year of research for federal and commercial customers. Our federal research efforts support initiatives for the department of health and human services and the department of defense. Mriglobal is committed to remaining well-positioned to advance the health and safety of our world. For example, we were optimally poised to respond to the priority needs of the global covid-19 crisis. We supported safety and efficacy evaluation of candidate treatments for covid-19, testing of disinfectant technologies, mask evaluations, development/application of covid-19 diagnostic testing, developing back-to-work/school safety plans for academic institutions and deploying several mobile laboratories and containment units to pandemic response efforts. With continued inves tment, mriglobal will continue to operate at forefront of disease prevention, treatment, and research.